Abbott's Amulet 360™ Wins CE Mark for Stroke Prevention in AFib Patients
Event summary
- Abbott received CE Mark for Amulet 360™, a next-generation device to reduce stroke risk in AFib patients.
- First European cases completed in Germany and Denmark, with expansion planned across Europe.
- VERITAS Study data shows 99.8% successful implantation and 93.9% complete LAA closure by 45 days.
- Amulet 360™ features a softer, more conformable design with smaller anchors for better LAA sealing.
- Fourth major electrophysiology approval for Abbott in just over a year.
The big picture
Abbott's Amulet 360™ approval strengthens its position in the electrophysiology market, following a series of recent regulatory wins. The device addresses a critical need for AFib patients who cannot tolerate long-term blood thinners, aligning with broader industry trends toward minimally invasive stroke prevention solutions. With four major approvals in a year, Abbott is rapidly expanding its portfolio, potentially capturing a larger share of the cardiac arrhythmia treatment market.
What we're watching
- Market Expansion
- The pace at which Abbott can expand Amulet 360™ adoption across Europe and other regions.
- Clinical Outcomes
- Whether long-term data will confirm the device's safety and efficacy in diverse patient populations.
- Competitive Positioning
- How Amulet 360™ will differentiate Abbott in the growing market for stroke prevention technologies.